Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
| Revenue (TTM) | $1.64B |
| Gross Profit (TTM) | $932.69M |
| EBITDA | $308.30M |
| Operating Margin | 10.40% |
| Return on Equity | -38.60% |
| Return on Assets | 2.54% |
| Revenue/Share (TTM) | $21.41 |
| Book Value | $13.39 |
| Price-to-Book | 1.46 |
| Price-to-Sales (TTM) | 0.94 |
| EV/Revenue | 2.003 |
| EV/EBITDA | 14.27 |
| Quarterly Earnings Growth (YoY) | 0.40% |
| Quarterly Revenue Growth (YoY) | 2.40% |
| Shares Outstanding | $77.80M |
| Float | $58.70M |
| % Insiders | 14.29% |
| % Institutions | 100.15% |
Volatility is currently expanding
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.
Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/cases/integra-lifesciences/ Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023 (the “Wrongdoing Period”.
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open.
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IART and any ticker you trade — then tracks every position and per-strategy win rate.
